166 results on '"Chim CS"'
Search Results
2. Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma
3. Trichostrongylus infestation masquerading as conditioning toxicity of the gut in bone marrow transplatation
4. Erratum: Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia
5. Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma
6. Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN
7. Multiple omics levels of chronic lymphocytic leukemia
8. Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells
9. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
10. Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
11. Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM
12. Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis
13. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
14. Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies
15. Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies
16. Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index
17. Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma
18. An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications
19. Conditional survival in multiple myeloma and impact of prognostic factors over time
20. miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication
21. SHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker
22. Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909)
23. Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma
24. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma
25. Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma
26. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis
27. microRNA-140-3p protects hippocampal neuron against pyroptosis to attenuate sevoflurane inhalation-induced post-operative cognitive dysfunction in rats via activation of HTR2A/ERK/Nrf2 axis by targeting DNMT1
28. Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data
29. Targeting HIC1/TGF-β axis-shaped prostate cancer microenvironment restrains its progression
30. NK-/T-cell lymphomas
31. Selective elimination of immunosuppressive T cells in patients with multiple myeloma
32. Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
33. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR
34. Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma
35. Salvage second transplantation in relapsed multiple myeloma
36. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma
37. Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
38. A simple additive staging system for newly diagnosed multiple myeloma
39. Genomic characterization of functional high-risk multiple myeloma patients
40. Association between gene promoter methylation of the one-carbon metabolism pathway and serum folate among patients with hyperhomocysteinemia
41. A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group
42. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
43. Extramedullary disease in multiple myeloma
44. Acute promyelocytic leukemia current treatment algorithms
45. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy
46. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options
47. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
48. Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification
49. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias
50. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.